ARID1A silencing seems to be inducing a subcellular redistribution of β-catenin from the plasma membrane to the cytoplasm and nucleus in gastric cancer, which was found to be significantly associated with worse clinical prognosis [51]. This evidence concerns the gene ARID1A and gastric cancer.